Adjuvant treatment with the anti-PD-1 agent pembrolizumab was evaluated in patients with AJCC7 stage IIIA (SLN >1 mm), IIIB or IIIC (without ITM) melanoma in the placebo-controlled EORTC 1325/KEYNOTE-054 trial. This evidence concerns the gene PDCD1 and melanoma.